Shares of Evoke Pharma Inc. (NASDAQ:EVOK) dropped 10% during trading on Tuesday . The stock traded as low as $2.30 and last traded at $2.34, with a volume of 935,245 shares. The stock had previously closed at $2.60.

EVOK has been the subject of several research analyst reports. Rodman & Renshaw reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evoke Pharma in a report on Monday, July 11th. Noble Financial downgraded Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. FBR & Co reiterated an “outperform” rating and set a $9.00 target price on shares of Evoke Pharma in a research report on Sunday, July 31st. Brean Capital reiterated a “buy” rating on shares of Evoke Pharma in a research report on Friday, July 8th. Finally, Northland Securities downgraded Evoke Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday, July 18th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $10.28.

The firm’s market cap is $16.15 million. The company’s 50-day moving average is $4.43 and its 200 day moving average is $4.68.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Monday, August 15th. The specialty pharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.02. Analysts predict that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In other news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.